





RealRate

PHARMACEUTICAL 2017

Zynerba Pharmaceuticals Inc. Rank 116 of 292



The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Zynerba Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 123% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	36,411
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,967
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	-28
Other Liabilities	0
Other Net Income	-208
Other Revenues	7.2
Property and Equipment	143
Research and Development	16,785
Selling, General and Administrative Expense	6,430

Output Variable	Value in 1000 USD
Assets	36,554
Liabilities	6,967
Expenses	23,187
Revenues	7.2
Stockholders Equity	29,587
Net Income	-23,389
Comprehensive Net Income	-23,389
Economic Capital Ratio	126%